CN112262157A - 化药抗性癌症的组合治疗 - Google Patents

化药抗性癌症的组合治疗 Download PDF

Info

Publication number
CN112262157A
CN112262157A CN201980031078.0A CN201980031078A CN112262157A CN 112262157 A CN112262157 A CN 112262157A CN 201980031078 A CN201980031078 A CN 201980031078A CN 112262157 A CN112262157 A CN 112262157A
Authority
CN
China
Prior art keywords
ror
antibody
chemotherapeutic agent
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980031078.0A
Other languages
English (en)
Chinese (zh)
Inventor
T·基普斯
S·张
E·M·吉亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN112262157A publication Critical patent/CN112262157A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN201980031078.0A 2018-03-09 2019-03-11 化药抗性癌症的组合治疗 Pending CN112262157A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862641035P 2018-03-09 2018-03-09
US62/641,035 2018-03-09
PCT/US2019/021694 WO2019173843A1 (en) 2018-03-09 2019-03-11 Combination treatment of chemoresistant cancers

Publications (1)

Publication Number Publication Date
CN112262157A true CN112262157A (zh) 2021-01-22

Family

ID=67846369

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980031078.0A Pending CN112262157A (zh) 2018-03-09 2019-03-11 化药抗性癌症的组合治疗

Country Status (6)

Country Link
US (1) US11883492B2 (https=)
EP (1) EP3762428A4 (https=)
JP (2) JP2021517135A (https=)
CN (1) CN112262157A (https=)
AU (1) AU2019231321B2 (https=)
WO (1) WO2019173843A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120865418A (zh) * 2025-09-28 2025-10-31 成都微芯新域生物技术有限公司 抗ror1抗体及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250008730A (ko) 2022-03-09 2025-01-15 산유 바이오파마슈티컬스 씨오., 엘티디. Ror1-표적화 결합 분자 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130273073A1 (en) * 2011-01-14 2013-10-17 The Regents Of The University Of California Therapeutic Antibodies against ROR-1 Protein and Methods for Use of Same
US20150232569A1 (en) * 2012-08-24 2015-08-20 The Regents Of The University Of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101807319B1 (ko) * 2008-11-22 2017-12-11 제넨테크, 인크. 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
WO2011143665A1 (en) * 2010-05-14 2011-11-17 Genentech, Inc. Treatment methods
MX2015007185A (es) * 2012-12-04 2017-09-05 Eisai R&D Man Co Ltd Uso de eribulina en el tratamiento de cancer de pecho.
EP3842072A1 (en) * 2015-05-18 2021-06-30 Eureka Therapeutics, Inc. Anti-ror1 antibodies
IL299099B2 (en) * 2016-06-27 2025-07-01 Univ California Cancer treatment combinations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130273073A1 (en) * 2011-01-14 2013-10-17 The Regents Of The University Of California Therapeutic Antibodies against ROR-1 Protein and Methods for Use of Same
US20150232569A1 (en) * 2012-08-24 2015-08-20 The Regents Of The University Of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHANG, S. ET AL: "Breast Cancer Initiating Cells Express Functional ROR1, Which Can Be Targeted By Cirmtuzumab To Potentially Mitigate The Risk Of Relapse After Therapy", 《POSTER IN 2017 SAN ANTONIO BREAST CANCER SYMPOSIUM》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120865418A (zh) * 2025-09-28 2025-10-31 成都微芯新域生物技术有限公司 抗ror1抗体及其应用
CN120865418B (zh) * 2025-09-28 2025-12-30 成都微芯新域生物技术有限公司 抗ror1抗体及其应用

Also Published As

Publication number Publication date
CA3093568A1 (en) 2019-09-12
US11883492B2 (en) 2024-01-30
US20210085786A1 (en) 2021-03-25
AU2019231321A1 (en) 2020-10-15
EP3762428A1 (en) 2021-01-13
AU2019231321B2 (en) 2026-01-29
WO2019173843A1 (en) 2019-09-12
EP3762428A4 (en) 2021-12-01
JP2021517135A (ja) 2021-07-15
JP2025063134A (ja) 2025-04-15

Similar Documents

Publication Publication Date Title
JP2023179437A (ja) キメラ抗原受容体組成物
CN111565722A (zh) 用于癌症治疗的腺苷路径抑制剂
JP7734661B2 (ja) 抗ｒｏｒ－２抗体および使用方法
JP2025063134A (ja) 化学療法抵抗性がんの組合せ処置
US20210023238A1 (en) Triptolide antibody conjugates
CN114514230A (zh) Mettl16抑制剂及其用途
CN116710429A (zh) IRE1α抑制剂及其用途
US11739121B2 (en) EPHA2 agonists and uses thereof
CN119365493A (zh) 抗-cd84抗体以及其用途
CN111587113A (zh) 用于癌症治疗的组合疗法
US20240415883A1 (en) Treatment of neuroendocrine cancers
HK40046118A (en) Combination treatment of chemoresistant cancers
CA3093568C (en) Combination treatment of chemoresistant cancers
US20240132887A1 (en) Protein arginine methyltransferase 9 inhibitors and methods of use
US20230340089A1 (en) Smc1a antibodies and uses thereof
KR20250129736A (ko) 항-ror-2 항체 및 사용 방법
KR20240046558A (ko) 항-수용체 관련 티로신 키나제 (ryk) 항체 및 이의 용도
WO2022197866A1 (en) Anti-hvem antibodies
HK40115498A (zh) 抗-cd84抗体以及其用途
HK40036025A (en) Combination therapy for cancer treatment
HK40036024A (en) Adenosine pathway inhibitors for cancer treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40046118

Country of ref document: HK